Latest Updates of Key Players in the Clinical Stage Biotechnology Market
Want to turn market confusion into confidence? Start with a free personalized Clinical Stage Biotechnology sample: Download Now
| Company | Headquarters | Latest Update |
| Tempus | United States | In January 2025, Tempus AI, Inc., a technology organization leading the adoption of AI to advance precision medicine, announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to support and inform testing decisions. |
| ElevateBio | United States | ElevateBio has continued to advance its research related to the breakthrough CRISPR gene editing technology, and treatments ranging from cancer to multiple sclerosis, diabetes, and Huntington’s Disease. |
| Biosplice Therapeutics | United States | In January 2026, Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced that it had submitted its NDA to the FDA for approval of its new therapy for the treatment of knee osteoarthritis. |
| Insitro | United States | In January 2026, AI-based therapeutics company insitro acquired biotechnology organization CombinAbleAI to complete its AI-based platform for drug discovery and design. |
| Recursion Pharmaceuticals | United States | In February 2026, Recursion, a leading clinical-stage TechBio organization decoding biology to radically improve lives, reported business updates and economic results. |
| Mirador Therapeutics | United States | In January 2026, Mirador accelerated its multi-asset clinical pipeline in immuno-fibrotic disease; it closed a $250 million series B with premier investors. |
Supply Chain Analysis
R&D:
- Research and development (R&D) for clinical-stage biotechnology includes optimizing drug formulation, scaling up manufacturing, obtaining regulatory approval (FDA/EMA), and conducting post-market surveillance.
- Key Players: Vertex Pharmaceuticals Incorporated and Alnylam Pharmaceuticals Inc.
Manufacturing Processes:
- Pharmaceutical ERP systems manage critical manufacturing technology such as upstream processing, downstream processing, and fill & finish.
- Key Players: Gilead Sciences Inc. and Regeneron Pharmaceuticals Inc.
Patient Services:
- Patient services in clinical-stage biotechnology organizations focus on enhancing the experience, safety, and retention of participants in clinical trials.
- Key Players: Moderna Inc. and BioNTech SE
Market Growth
The global clinical stage biotechnology market size was estimated at USD 47.19 billion in 2025 and is predicted to increase from USD 54.66 billion in 2026 to approximately USD 205.32 billion by 2035, expanding at a CAGR of 15.84% from 2026 to 2035.
Recent Developments in the Clinical Stage Biotechnology Market
- In March 2026, Gilead Sciences, Inc. announced it had entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.
- In September 2025, Roche announced that it had entered into a definitive merger agreement to acquire 89bio, Inc., a publicly listed clinical-stage biopharmaceutical organization pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking